Highest-materiality recent filing
Whitehawk Therapeutics shareholders elect three Class III directors at annual meeting
Behzad Aghazadeh, Richard Maroun, and Emma Reeve elected as Class III directors with 26.7M, 27.7M, and 27.7M votes for, respectively.
Whitehawk Therapeutics expands ADC pipeline with option for CPT113 in up to five new programs
Option agreement with Hangzhou DAC provides access to CPT113 for up to five internally developed ADC programs, including dual-payload variations.
Whitehawk Therapeutics raises $87.5M in PIPE, extends cash runway into H2 2028
Sells 4.33M shares at $3.92/share and 17.99M pre-funded warrants at $3.9199/warrant.
Whitehawk Therapeutics Q1 net loss $22.2M; cash $123M funds into 2028
Net loss of $22.2M for Q1 2026 vs net income of $73.0M in Q1 2025, which included an $87.4M gain on sale of Aadi Subsidiary.
Whitehawk reports FY2025 net loss $20.6M (incl $87.3M gain); cash $145.7M, two Phase 1 ADCs
FY2025 net loss $20.6M includes $87.3M gain on AADI divestiture; Q4 net loss $23.3M vs $18.3M prior-year quarter.
Whitehawk Therapeutics reports Q3 net loss of $17.7M, cash $162.6M, IND filings on track
Net loss for Q3 2025 was $17.7M vs $12.5M in Q3 2024; no revenue reported.
Whitehawk Q2 net loss $52.6M; cash $177.2M, runway to 2028
Net loss of $52.6M vs $14.6M Q2 2024; includes $38M upfront payment under Wuxi ADC deal.
Whitehawk Therapeutics shareholders elect three Class II directors at annual meeting
Three Class II directors elected: Anupam Dalal (18.5M for, 5.0M withheld), Mohammad Hirmand (19.4M for, 4.2M withheld), David Lennon (19.4M for, 4.2M withheld).
Whitehawk Q1 net income $73M on divestiture gain; cash $231M, expects $185M into 2028
Q1 2025 net income of $73.0M includes $87.4M gain from Aadi Sub divestiture; ex-gain net loss $14.4M.
Sale closed March 25, 2025; total cash proceeds of $102.4M after purchase-price adjustments.
Whitehawk completes sale of Aadi Subsidiary to Kaken for $102.4M cash
Sale of 100% of Aadi Subsidiary, Inc. to KAKEN INVESTMENTS INC. closed on March 25, 2025.
Name changed to Whitehawk Therapeutics; stock begins trading under 'WHWK' on Nasdaq effective March 19, 2025.
Aadi Bioscience closes $100M PIPE; stockholders approve divestiture of FYARRO business
Gross proceeds of $100M from PIPE led by Ally Bridge Group; 21.6M shares at $2.40 and 20.1M pre-funded warrants at $2.3999.
Aadi Bioscience sells subsidiary for $100M, licenses ADC programs, raises $100M PIPE
Sells wholly owned subsidiary Private Aadi to Kaken Investments for $100M; stockholder approval required.
Aadi Bioscience Q3 2024 FYARRO sales $7.2M (+21% YoY); net loss $12.5M
FYARRO net product sales of $7.2M in Q3 2024, up 17% from Q2 2024 and 21% from prior year.
Aadi Bioscience wins arbitration; panel finds no breach, no damages to EOC
Arbitration panel issued Final Award on Sept 26, 2024, in favor of Aadi Bioscience.
CEO David J. Lennon eligible for $390,000 retention bonus if employed through Mar 31, 2025 or Change of Control.
CMO Loretta Itri resigns; Executive Chairman Neil Desai steps down on Oct 1, 2024
CMO Dr. Loretta Itri voluntarily resigns effective Oct 1, 2024; receives 12 months severance pay plus COBRA reimbursement.
PRECISION1 trial halted; IDMC found it unlikely to meet efficacy threshold for accelerated approval; 25 benefiting patients eligible for expanded access.
Aadi Bioscience Q2 FYARRO sales $6.2M, net loss $14.6M; PRECISION1 interim analysis Q3
FYARRO net product sales $6.2M for Q2 2024, up 15% quarter-over-quarter, flat YoY.
Elected Caley Castelein (9.95M for, 1.91M withheld) and Neil Desai (8.17M for, 3.68M withheld) as Class I directors.
Aadi Bioscience Q1 FYARRO sales $5.4M; PRECISION1 fully enrolled; net loss $18.3M
FYARRO net sales $5.4M, down 8.8% YoY due to distributor ordering and fewer patient initiations.
Aadi Bioscience amends FYARRO supply agreement with Fresenius Kabi, extends term to July 31, 2024
Amendment effective March 31, 2024 extends supply agreement for FYARRO through July 31, 2024 (or later agreed date).
Aadi Bioscience reports FY2023 revenue $24.4M (+60% YoY); net loss $65.8M
FYARRO net sales $24.4M for FY2023, up 60% YoY; Q4 sales $6.3M (+21% YoY).
Aadi Bioscience reports 26% ORR in TSC1 arm, 11% in TSC2 arm from PRECISION1 interim analysis
TSC1 arm (n=22): 26% ORR (5 PRs, 4 confirmed), 42% clinical benefit rate, median 3 prior therapies.
FYARRO sales $6.0M in Q3 2023, up 40% YoY from $4.2M; net loss $16.3M vs $14.5M.
Aadi Bioscience reports Q3 2023 results; no financial details in filing
Press release for Q3 2023 results issued on November 8, 2023.
Aadi appoints Dave Lennon as President and CEO; base salary $640K, option for 490K shares
David J. Lennon appointed President and CEO, effective Oct 2, 2023; Scott Giacobello returns to CFO role.
Aadi Bioscience Q2 FYARRO sales $6.2M (+80% YoY); advancing PRECISION1 and new trials
FYARRO net product sales $6.2M in Q2 2023, up ~6% QoQ and 80% YoY from $3.4M.
Aadi Bioscience annual meeting elects directors, says-on-pay passes, auditor ratified
Elected three Class III directors: Aghazadeh (8.36M for), Maroun (9.87M), Reeve (9.87M).
FYARRO net product sales $5.9M, up 12% QoQ from $5.2M in Q4 2022 and $2.3M in Q1 2022.
Scott Giacobello appointed Interim CEO and President effective March 15, 2023; remains CFO.
Aadi Bioscience reports FY2022 revenue $15.2M; PRECISION-1 data Q2 2023
FY 2022 total revenue $15.2M from FYARRO (10 months); Q4 net product sales $5.2M (+23% QoQ).
Aadi Bioscience CEO Brendan Delaney resigns; CFO Scott Giacobello named interim CEO
Brendan Delaney resigned as President, CEO, and director effective March 14, 2023, for personal reasons, not due to any disagreement.
Aadi Bioscience amends supply agreement with Fresenius Kabi for Fyarro; term extended to March 2024
Amendment extends contract term to March 31, 2024 (or later date if agreed).
Aadi Bioscience amends bylaws to revise director nomination procedures and conform to Delaware law
Board amended and restated bylaws effective Dec 6, 2022, adding requirement for stockholders to deliver Rule 14a-19 compliance evidence 5 business days before meeting.
AADI Bioscience regains compliance with Nasdaq audit committee independence rule
Non-compliance resulted from Dr. Karin Hehenberger not qualifying as independent per Nasdaq Listing Rule 5605(c)(2)(A).
Aadi Bioscience Q3 revenue $4.2M; Desai to Executive Chairman, Delaney named CEO
Net product sales of FYARRO $4.2M in Q3 2022, up 24% from Q2; net loss $14.5M (vs $87.1M in Q3 2021).
Aadi Bioscience raises $72.5M in PIPE financing to extend cash runway into 2025
PIPE includes 3,373,526 shares at $12.50 and 2,426,493 pre-funded warrants at $12.4999 with $0.0001 exercise price.
Aadi Bioscience Q2 2022: FYARRO sales $3.4M, net loss $18.3M, cash $118.7M
FYARRO net product sales $3.4M for Q2 2022, first full quarter after launch.
Aadi Bioscience receives termination notice from EOC Pharma for FYARRO license in Greater China
EOC Pharma terminated FYARRO license agreement for Greater China effective June 27, 2022.
Aadi Bioscience stockholders elect two directors, ratify BDO as auditor
Anupam Dalal elected with 11,291,829 votes for and 454,197 withheld; 3,353,501 broker non-votes.
Net product sales of FYARRO were $2.3M for partial first quarter since launch in Feb 2022.
Aadi Bioscience reports Q4 2021 net loss of $16M; FYARRO launched Feb 2022
FYARRO approved Nov 2021 for malignant PEComa; launched Feb 2022; added to NCCN as preferred therapy.
Aadi Bioscience enters $75M ATM equity offering agreement with Cowen
ATM facility allows Aadi to sell up to $75M in common stock at its discretion.
Aadi Bioscience enters manufacturing agreement with Fresenius Kabi for Fyarro
Fresenius Kabi to manufacture Fyarro (sirolimus protein-bound) for Aadi under a purchase-order basis.
Aadi Bioscience receives FDA approval for FYARRO in advanced malignant PEComa
FDA approved FYARRO (sirolimus protein-bound particles) for adult patients with advanced unresectable or metastatic malignant PEComa.
Aadi Q3 net loss $87.2M; FYARRO PDUFA Nov 26; cash $161.4M
FYARRO (nab-sirolimus) NDA under FDA priority review with PDUFA target Nov 26, 2021.
Aadi appoints Scott Giacobello as CFO, replacing interim CFO Lance Thibault
Scott Giacobello appointed CFO and Treasurer, effective Nov 28, 2021; part-time from Nov 1.
Old Aadi reported net loss of $3.5M for 2020, revenue of $14.6M (primarily $14M license revenue).
On August 16, 2024, Loretta Itri, M.D. notified the board of directors of the Company (the “Board”) that her employment as Chief Medical Officer will cease effective October 1, 2024.
On August 20, 2024, Neil Desai, Ph.D, was notified that his employment as Executive Chairman of the Company will cease on October 1, 2024.
the Board of Directors (the “ Board ”) of Aadi Bioscience, Inc. (the “ Company ”) appointed David J. Lennon, Ph.D., to serve as the Company’s President and Chief Executive Officer and principal executive officer, effective as of October 2, 2023
Mr. Giacobello has served as the Company’s Interim CEO and President and principal executive officer since March 15, 2023, and will continue to serve as the Company’s Chief Financial Officer, a position he has held since November 2021, following Dr. Lennon’s appointment.
the Board increased the Board’s size from eight (8) to nine (9) directors and appointed Dr. Lennon to fill the resulting vacancy
appointed Scott Giacobello as the Company’s Interim Chief Executive Officer and President, effective March 15, 2023.
On March 24, 2023, Mohammad Hirmand, M.D. was appointed a Class II director by the Board of Directors (the “ Board ”) of the Company, effective March 27, 2023.
On March 2, 2023, Brendan Delaney submitted a letter to the Board of Directors (the “Board”) of Aadi Bioscience, Inc. (the “Company”) resigning from his position as the Company’s President and Chief Executive Officer (“CEO”) and as a member of the Board of Directors, effective March 14, 2023.
Effective March 15, 2023, the Board appointed Scott Giacobello, the Company’s Chief Financial Officer, to serve as the Company’s Interim CEO and President and principal executive officer.
the Board increased the Board’s size from seven (7) to eight (8) directors and elected Mr. Delaney to fill the resulting vacancy, effective as of the Effective Date.
and Brendan Delaney, Chief Operating Officer, to President and Chief Executive Officer of the Company, effective as of January 1, 2023
the appointment of Neil Desai, founder, director, President and Chief Executive Officer of the Company, to Executive Chairman of the Company
Max materiality 0.95 · Median 0.62 · Most common event other_material